Orlistat / TumCI Cancer Research Results

OLST, Orlistat: Click to Expand ⟱

Features:

Orlistat (tetrahydrolipstatin; anti-obesity drug; OTC 60 mg, Rx 120 mg). A potent, minimally absorbed gastrointestinal lipase inhibitor that reduces dietary fat absorption (~30% at 120 mg TID).

Primary mechanisms (conceptual rank):
1) Irreversible inhibition of gastric + pancreatic lipases (↓ triglyceride hydrolysis)
2) ↓ Chylomicron formation → ↓ systemic lipid flux
3) Secondary metabolic shifts (weight loss–mediated insulin sensitivity changes)

Bioavailability / PK relevance: Very low systemic absorption (<1%); primary action is intraluminal in gut. Most systemic mechanistic cancer data derive from higher in-vitro concentrations or off-target effects (e.g., FASN inhibition).

In-vitro vs oral exposure: Many anti-cancer studies use concentrations likely exceeding achievable plasma levels from standard dosing (qualifier: high concentration only for direct tumor cytotoxicity).

Clinical evidence status: Approved for obesity; cancer evidence largely preclinical/observational; no robust oncology RCT indication.

Inhibits lipase and is used to facilitate weight loss.

Orlistat — Cancer vs Normal Cell Pathway Map

Rank	Pathway / Axis	Cancer Cells	Normal Cells	TSF	Primary Effect	Notes / Interpretation
1	Fatty Acid Synthase (FASN)	↓ (high concentration only)	↔ (low FASN dependence)	R/G	Lipid synthesis blockade; apoptosis	Well-known off-target in vitro; many tumors overexpress FASN. Clinical relevance limited by low systemic exposure.
2	Lipid availability / metabolic flux	↓ (indirect)	↓ (systemic)	G	Reduced lipid supply	Weight-loss–mediated effect; may indirectly reduce pro-tumor metabolic signaling (insulin/IGF axis).
3	PI3K/AKT/mTOR	↓ (model-dependent)	↔ / ↓ (metabolic improvement)	R/G	Reduced anabolic signaling	Often secondary to lipid stress or metabolic shifts; not primary gut mechanism.
4	Apoptosis (caspase activation)	↑ (high concentration only)	↔	R/G	Programmed cell death	Observed in cancer lines at supra-physiologic levels; translation uncertain.
5	ROS / lipid peroxidation stress	↑ (lipid stress–related; model-dependent)	↔	P/R	Metabolic oxidative stress	Linked to FASN inhibition; not central to approved mechanism.
6	NRF2 axis	↔ (insufficient evidence)	↔	R/G	Not a dominant axis	No consistent evidence of primary NRF2 modulation at therapeutic exposure.
7	Ferroptosis (lipid metabolism link)	↑ (theoretical / model-dependent)	↔	R/G	Lipid vulnerability shift	FASN inhibition could alter lipid composition; ferroptosis relevance remains investigational.
8	HIF-1α / Warburg coupling	↓ (indirect; metabolic improvement)	↔	G	Reduced pro-growth metabolic signaling	Likely secondary to weight loss and insulin reduction rather than direct tumor action.
9	Ca²⁺ signaling	↔	↔	P/R	No primary role	Not a recognized mechanistic axis for orlistat.
10	Clinical Translation Constraint	↓ (constraint)	↓ (constraint)	—	Minimal systemic exposure	Low absorption limits direct anti-tumor applicability; GI side effects and fat-soluble vitamin malabsorption noted.

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr

TumCI, Tumor Cell invasion: Click to Expand ⟱

Source:

Type:

Tumor cell invasion is a critical process in cancer progression and metastasis, where cancer cells spread from the primary tumor to surrounding tissues and distant organs. This process involves several key steps and mechanisms:

1.Epithelial-Mesenchymal Transition (EMT): Many tumors originate from epithelial cells, which are typically organized in layers. During EMT, these cells lose their epithelial characteristics (such as cell-cell adhesion) and gain mesenchymal traits (such as increased motility). This transition is crucial for invasion.

2.Degradation of Extracellular Matrix (ECM): Tumor cells secrete enzymes, such as matrix metalloproteinases (MMPs), that degrade the ECM, allowing cancer cells to invade surrounding tissues. This degradation facilitates the movement of cancer cells through the tissue.

3.Cell Migration: Once the ECM is degraded, cancer cells can migrate. They often use various mechanisms, including amoeboid movement and mesenchymal migration, to move through the tissue. This migration is influenced by various signaling pathways and the tumor microenvironment.

4.Angiogenesis: As tumors grow, they require a blood supply to provide nutrients and oxygen. Tumor cells can stimulate the formation of new blood vessels (angiogenesis) through the release of growth factors like vascular endothelial growth factor (VEGF). This not only supports tumor growth but also provides a route for cancer cells to enter the bloodstream.

5.Invasion into Blood Vessels (Intravasation): Cancer cells can invade nearby blood vessels, allowing them to enter the circulatory system. This step is crucial for metastasis, as it enables cancer cells to travel to distant sites in the body.

6.Survival in Circulation: Once in the bloodstream, cancer cells must survive the immune response and the shear stress of blood flow. They can form clusters with platelets or other cells to evade detection.

7.Extravasation and Colonization: After traveling through the bloodstream, cancer cells can exit the circulation (extravasation) and invade new tissues. They may then establish secondary tumors (metastases) in distant organs.

8.Tumor Microenvironment: The surrounding microenvironment plays a significant role in tumor invasion. Factors such as immune cells, fibroblasts, and signaling molecules can either promote or inhibit invasion and metastasis.

Scientific Papers found: Click to Expand⟱

1225-

OLST,

Orlistat Induces Ferroptosis in Pancreatic Neuroendocrine Tumors by Inactivating the MAPK Pathway

vitro+vivo,

PC,

TumCMig↓, TumCI↓, Ferroptosis↑, MAPK↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Redox & Oxidative Stress ⓘ

Ferroptosis↑, 1,

Cell Death ⓘ

Ferroptosis↑, 1, MAPK↓, 1,

Migration ⓘ

TumCI↓, 1, TumCMig↓, 1,
Total Targets: 5

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: TumCI, Tumor Cell invasion

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:14  Target#:324  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid